Agilent v. Synthego: Federal Circuit Affirms CRISPR Guide RNA Patent Unpatentable
Agilent Technologies appealed a finding that US10900034B2 — covering modified guide RNAs in CRISPR/Cas systems — was unpatentable. The Federal Circuit affirmed the ruling in full, closing a 687-day appellate battle with significant consequences for CRISPR IP portfolios across the life sciences sector.
Federal Circuit locks in CRISPR guide RNA invalidity for Agilent
Agilent Technologies, Inc. — a major life-sciences instrumentation and reagent company — appealed a patentability determination concerning US10900034B2, a patent claiming modified guide RNAs and their use in CRISPR/Cas gene-editing systems. The appeal, docketed as Case No. 23-2187, was filed at the Court of Appeals for the Federal Circuit on 25 July 2023. Synthego Corporation, a synthetic biology company specialising in CRISPR genome-editing tools, prevailed as the appellee.
The Federal Circuit issued its judgment on 11 June 2025, affirming the underlying finding of unpatentability in full. The court’s order — ‘AFFIRMED’ — confirms that the lower-tribunal determination that US10900034B2 is unpatentable stands as the final legal resolution. For Agilent, this means the patent can no longer be enforced, and any licensing or exclusivity strategy built around it is effectively extinguished at this level of review.
At 687 days, the appellate proceedings ran for nearly two years, consistent with contested Federal Circuit patentability appeals involving complex biotechnology claims. The public record does not disclose whether a panel opinion or Rule 36 summary affirmance was issued, which would bear on the precedential weight of the ruling. What drove the affirmance — whether anticipation, obviousness, or a written-description deficiency — is not specified in the available case data, leaving open the precise doctrinal basis for practitioners to monitor.
Filing to Unpatentable in 687 days
687 days from filing to Federal Circuit decision — longer than the median Federal Circuit appeal
Federal Circuit affirms: what the unpatentability ruling means for both parties
What ‘AFFIRMED’ means at the Federal Circuit
An affirmance at the Federal Circuit means the appellate panel reviewed the record and found no reversible legal or factual error in the tribunal below. The underlying unpatentability determination is now final at the federal appellate level. Agilent’s only remaining avenue would be a petition for en banc rehearing or, exceptionally, certiorari to the Supreme Court — both of which face very high bars.
No reversible error foundAgilent loses enforceability of its CRISPR guide RNA patent
With the unpatentability ruling affirmed, US10900034B2 is no longer a valid, enforceable patent. Agilent cannot assert it against competitors, license it for royalties, or use it as leverage in portfolio cross-licensing. Any existing licences tied exclusively to this patent are also undermined. The ruling effectively removes a key IP asset from Agilent’s CRISPR reagent portfolio at the appellate stage.
Patent extinguished on appealSynthego’s freedom to operate in CRISPR guide RNA space confirmed
Synthego, as the prevailing appellee, benefits from a final determination that the asserted patent is unpatentable. This confirms Synthego’s freedom to operate with respect to the modified guide RNA technology claimed in US10900034B2 without risk of infringement liability under this specific patent. The ruling raises the bar significantly for Agilent to re-assert equivalent claims in the CRISPR guide RNA space.
FTO confirmed for SynthegoCRISPR guide RNA IP landscape shifts after Agilent loss
The affirmance signals that at least one asserted foundational CRISPR guide RNA patent has not survived adversarial review, which may embolden other CRISPR tool companies to challenge related patents in the space. For R&D teams and product developers working with modified guide RNAs and CRISPR/Cas systems, the ruling reduces one layer of IP risk — though the broader CRISPR patent landscape remains heavily contested.
CRISPR IP risk recalibratedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Agilent Technologies, Inc. | Company | Life-sciences instrumentation and reagents company — holder of US10900034B2Search in Eureka ↗ |
| Defendant | Synthego, Corp. | Company | Synthego Corp. — synthetic biology company specialising in CRISPR genome-editing tools and reagentsSearch in Eureka ↗ |
| Plaintiff counsel | Aaron Hand | Attorney | Counsel for Agilent Technologies, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Denise Marie De Mory | Attorney | Counsel for Agilent Technologies, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Mark A. Lemley | Attorney | Counsel for Agilent Technologies, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Rebecca Weires Setrakian | Attorney | Counsel for Agilent Technologies, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Bunsow DeMory LLP | Law Firm | Representing Agilent Technologies, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Lex Lumina LLP | Law Firm | Representing Agilent Technologies, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Morrison & Foerster LLP | Law Firm | Representing Agilent Technologies, Inc.Search in Eureka ↗ |
| Defendant counsel | Derek C. Walter | Attorney | Counsel for Synthego, Corp.Search in Eureka ↗ |
| Defendant counsel | Edward R. Reines | Attorney | Counsel for Synthego, Corp.Search in Eureka ↗ |
| Defendant law firm | Jones Day | Law Firm | Representing Synthego, Corp.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Appeals for the Federal CircuitSearch in Eureka ↗ |
Official order — verbatim text
The Federal Circuit’s order — ‘AFFIRMED’ — in a patentability/invalidity action carries decisive legal weight. At the appellate level, affirmance means the court applied the applicable standard of review (typically substantial evidence for factual findings, de novo for legal conclusions) and found the record fully supported the unpatentability determination below. For Agilent, this forecloses further challenge at the circuit level; for Synthego and the broader CRISPR sector, the ruling removes US10900034B2 as an enforceable IP barrier.
US10900034B2 — Modified Guide RNAs for CRISPR/Cas Gene-Editing Systems
US10900034B2, filed under application number US14/757204, claims modified guide RNA molecules and their use in CRISPR/Cas (clustered, regularly interspaced, short palindromic repeats/CRISPR-associated protein) systems. Guide RNAs are the programmable molecules that direct Cas nucleases to specific genomic targets — a foundational element of modern gene-editing technology. Chemical modifications to guide RNAs can improve stability, specificity, and delivery, making such claims commercially and scientifically significant.
Modified guide RNA patents sit at the core of the CRISPR tooling IP wars, with multiple parties — including the Broad Institute, UC Berkeley, and commercial entities — asserting overlapping rights. Agilent’s now-invalidated patent represented a potential enforcement vector against CRISPR reagent suppliers and research tool companies. With the Federal Circuit affirming unpatentability, competitors and licensees operating in this space face reduced — but not eliminated — IP exposure, as related family members or parallel patents may still be asserted.
Should your team run an FTO against US10900034B2 and its patent family?
Any R&D team or product group developing, manufacturing, or commercialising modified guide RNAs for CRISPR/Cas applications should note that US10900034B2 is now affirmed unpatentable. However, freedom-to-operate analysis cannot stop there: Agilent’s broader patent family — including continuations and divisionals filed under related applications — may contain overlapping claims that remain active and enforceable. An FTO based solely on this case outcome could leave residual risk unaddressed.
PatSnap Eureka’s FTO Search Agent enables life-sciences IP and R&D teams to map the full Agilent CRISPR guide RNA patent family, identify live continuation claims, and cross-reference your product’s technical features against the specific claim scope of each surviving family member. Run a structured FTO search before advancing modified guide RNA products to commercialisation — the invalidated patent is one data point, not a clean clearance.
Run a freedom-to-operate analysis on US10900034B2 to assess your product’s exposure
Run FTO in Eureka →Similar Federal Circuit CRISPR and gene-editing patent validity cases
Federal Circuit appeals involving CRISPR, guide RNA, and gene-editing patentability disputes — with analysis of invalidity outcomes and claim construction rulings.
What this case signals for the CRISPR and gene-editing IP landscape
A Federal Circuit affirmance of unpatentability in CRISPR guide RNA technology has ripple effects for every company operating in the genome-editing space.
CRISPR tool patents face real invalidity risk at the Federal Circuit
This ruling confirms that even well-resourced patentees like Agilent — represented by Morrison & Foerster and Lex Lumina — cannot guarantee appellate reversal of an unpatentability finding. Companies asserting or defending against CRISPR guide RNA patents should treat Federal Circuit affirmance as a realistic outcome and price that risk into licensing negotiations.
Synthego’s FTO win sets a precedent for CRISPR reagent competitors
The confirmation that US10900034B2 is unpatentable clears IP overhead for companies making or selling modified guide RNA products. Competitors should cross-reference their product claims against the now-invalid patent scope and assess whether related Agilent portfolio patents pose residual risk — the family may contain continuations with overlapping claims still in force.
Agilent v Synthego — key questions answered
The Federal Circuit affirmed the unpatentability of US10900034B2 in Case No. 23-2187, closing the appeal on 11 June 2025. The court found no reversible error in the lower determination, making the invalidity ruling final at the appellate level. Agilent’s patent covering modified guide RNAs for CRISPR/Cas systems is no longer enforceable.
US10900034B2 (application no. US14/757204) claims modified guide RNA compositions and methods for use in CRISPR/Cas gene-editing systems. Modified guide RNAs are commercially critical — they improve nuclease specificity and stability. The patent was contested in an invalidity/cancellation action by Synthego Corp., a CRISPR genome-editing tools company, on patentability grounds.
At the Federal Circuit, ‘AFFIRMED’ means the appellate panel reviewed the lower tribunal’s record and legal conclusions and found no reversible error. The unpatentability determination is now the final legal word at the circuit level. Agilent’s remaining options are limited to en banc rehearing petition or Supreme Court certiorari — both of which face exceptionally high thresholds.
The ruling directly invalidates US10900034B2 only. However, it may carry persuasive weight in related proceedings involving similar guide RNA claims, particularly where the same prior art or patentability arguments are raised. Practitioners should monitor whether Agilent holds continuation or divisional patents with overlapping claim scope that remain active, as those are not affected by this ruling.
Agilent was represented by Morrison & Foerster LLP, Bunsow DeMory LLP, and Lex Lumina LLP, with counsel including Mark A. Lemley, Denise Marie De Mory, Aaron Hand, and Rebecca Weires Setrakian. Synthego was represented by Jones Day, with Edward R. Reines and Derek C. Walter as lead counsel — a team with a strong Federal Circuit patent validity track record.
PatSnap Eureka searches patents and litigation data to answer instantly.